Captopril mitigates splenomegaly and myelofibrosis in the Gata1 low murine model of myelofibrosis

作者：Seth J. Corey, Jyoti Jha, Elizabeth A. McCart, W. Bradley Rittase, Jeffy George, Joseph J. Mattapallil, Hrishikesh Mehta, Ognoon Mungunsukh, Michelle A. Bylicky, Thomas A. Summers, Regina M. Day · 发表于：Journal of Cellular and Molecular Medicine · 年份：2018 · DOI：10.1111/jcmm.13710 · 被引用次数：14 · 研究领域：Myeloproliferative Neoplasms: Diagnosis and Treatment、Renin-Angiotensin System Studies、Multiple Myeloma Research and Treatments

Abstract Allogeneic stem cell transplantation is currently the only curative therapy for primary myelofibrosis (MF), while the JAK2 inhibitor, ruxolitinib. Has been approved only for palliation. Other therapies are desperately needed to reverse life‐threatening MF. However, the cell(s) and cytokine(s) that promote MF remain unclear. Several reports have demonstrated that captopril, an inhibitor of angiotensin‐converting enzyme that blocks the production of angiotensin II (Ang II), mitigates fibrosis in heart, lung, skin and kidney. Here, we show that captopril can mitigate the development of MF in the Gata1 low mouse model of primary MF. Gata1 low mice were treated with 79 mg/kg/d captopril in the drinking water from 10 to 12 months of age. At 13 months of age, bone marrows were examined for fibrosis, megakaryocytosis and collagen expression; spleens were examined for megakaryocytosis, splenomegaly and collagen expression. Treatment of Gata1 low mice with captopril in the drinking water was associated with normalization of the bone marrow cellularity; reduced reticulin fibres, splenomegaly and megakaryocytosis; and decreased collagen expression. Our findings suggest that treating with the ACE inhibitors captopril has a significant benefit in overcoming pathological changes associated with MF.